



May 28, 2022

Dept. of Corporate Services,
BSE Ltd.,
P J Towers,
Dalal Street,
Mumbai – 400 001.

Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East),
Mumbai 400051.

BSE Scrip Code : 524735

NSE Symbol : HIKAL

Dear Sir/ Madam,

**Subject: Results Presentation of the Company for the quarter and financial year ended
March 31, 2022**

With reference to the subject, we are enclosing a copy of the Results presentation on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2022.

This is for your information and records.

Thank you,

Yours sincerely,
for HIKAL LIMITED,

RAJASEKHAR
REDDY
CHINTAKINDI

Rajasekhar Reddy
Company Secretary

Encl: As above.

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11. CBD Belapur, Navi Mumbai - 400 614. Ind1a. Tel. + 91-22-3097 3100. Fax : + 91 -22-2757 4277

Regd. Office: 717, Maker Chambers -5, Nariman Point, Mumbai - 400 021, India. Tel. + 91 -22-3926 7100, +91-22 6277 0477. Fax: + 91-22-2283 3913

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028



Results Presentation - Q4 FY22

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



Jai Hiremath

"For the financial year '22, we achieved a PAT of Rs 161 Crores, which is a growth of 21% as compared to last financial year. Our Board of Directors has recommended a final dividend of Rs 0.40 per share (20% of FV). Along with an interim dividend of Rs. 1.20 per share (60% of FV) declared in February 2022, the total dividend for FY22 stands at Rs 1.60 per share (80% of FV).

On 6th Jan 2022, an unfortunate incident occurred at Sachin GIDC, Surat. Allegations were made that the tanker involved was carrying a by-product which allegedly came from Hikal's Talaja factory. All relevant employees of Hikal have voluntarily co-operated in the ongoing investigation. Since then, there has been a judicial recognition of the non-existent role of Hikal and its employees in the entire incident, as elucidated by the Hon'ble Gujarat High Court in its order. The matter is still sub-judice and presently the Company is in a very strong legal position. As a result of the Sachin GIDC incident the MPCB had given a closure notice to the Talaja factory. We have provided all the documents to MPCB and are confident of resolving the issue on the closure notice at the earliest.

The revenue for pharmaceutical business saw a muted growth of 3% and stood at Rs. 307 Crores in Q4 FY22. It was in line with the recent trend witnessed by the API industry due to strong transient headwinds of softening demand and disruptions in global supply chains. This combined with the challenging raw material disruptions and significant increase in input costs has seen a pressure on our margins in Q4 which we expect to continue through the first half of the year. On a positive side, we continued to receive new inquiries from global innovator companies in the CDMO business segment. We expect this segment to be a lead growth driver in the next few years.

The Crop Protection business revenue stood at Rs 194 Crores in Q4 FY22. We continued to face raw material availability challenges for some of our key products. However, the demand remains strong in the market. We will continue developing alternate domestic suppliers to mitigate future supply chain disruptions. We are investing in new capacity addition, which is expected to come on stream in second half of this financial year. On the CDMO front, we continued receiving several new inquiries and are working on a portfolio of new products for global innovator companies.

This year has marked the beginning of our strategic transformation journey, 'Pinnacle Program'. The program is seeing good momentum along with positive changes across both businesses. Along with a leading management consultant, we have developed a clear set of priorities for the growth of our Company over next five years through a new strategic direction. This will help reach our bold aspiration of driving profitable as well as sustainable growth and transforming our business to go from 'Good to Great'.

As the industry faces strong headwinds due to the inflationary pressures and a sharp rise in input costs of raw material, energy and solvents, we expect growth to be tapered and margins to be contract in the next year. We will continue to focus on passing through increased input costs to our customers. However, we do expect longer lead times given the inflationary pressures even customers are facing. To counteract the challenging environment, we continue to undertake multiple cost reduction as well as operational efficiency improvement initiatives within our business excellence program to minimize the impact of rising cost on our margins.

We expect FY 2022-23 to be a challenging year, one of consolidation and the following year we will return to sustainable and profitable growth".



Quarterly Financials Highlights

Financial Highlights - Q4 FY22



Revenue - Q4 FY22
Rs. 502 Crore



YoY
-6%



QoQ
-2%



EBITDA - Q4 FY22
Rs. 61 Crore



YoY
-44%



QoQ
-34%



EBITDA Margin - Q4 FY22
12.2%



YoY
-837 bps



QoQ
-591 bps



PAT - Q4 FY22
Rs. 21 Crore



YoY
-59%



QoQ
-54%



EPS - Q4 FY22
Rs 1.68




YoY
-59%




QoQ
-54%

Quarterly Performance Highlights


Revenue



EBIDTA




PAT



Rs. Crore


Performance Highlights

- Revenue marginally decreased by 6% on YoY basis to Rs 502 Cr in Q4 FY22 due to
 - Global slowdown in Generics business due to channel inventory and lower demand/off-take
 - Production delays due to unavailability of key raw materials caused by global supply chain and logistics disruptions
- EBITDA was at Rs 61 Cr due to transient external headwinds such as:
 - Increase in input costs of raw materials, energy and solvents on account of uncertainties arising out of Ukraine-Russia conflict as well as reemergence of Covid cases in China
 - Lag in pass through of costs to customers
- Lower operating margins resulted into lower PAT was Rs 21 Cr
- Board recommended final dividend of Rs 0.40 per share (20% of FV); the total dividend for FY22 stands at Rs 1.60 per share (80% of FV)
- Hikal's long term credit rating is maintained A+ by ICRA
- Capital expenditure to build a production facility at Panoli, Gujarat has initiated as part of 10-year multi-product animal health contract
- Traction from global innovator companies continued for CDMO segment of Pharmaceuticals and Crop Protection businesses
- Business excellence program is in progress with an aim to achieve higher throughput and lower cost of production from existing assets



Pharmaceuticals - Performance Highlights

- Revenue remained largely flat at Rs 308 Cr on YoY basis due to lower off-take by customers
- EBIT stood at Rs 30 Cr due to
 - Increase in key raw materials and energy cost due to global supply chain disruptions
 - Lag in passing the increased costs to the customers
- Significant focus on cost reduction and efficiency improvement projects to minimize the impact of rise in input cost
- Developed alternate suppliers to ensure supply chain security
- Order received for validation of an intermediate for a new potential drug from a leading global innovator company
- Significant traction in inquiries for emerging Animal Health business from several global innovator companies
- Acquired several new generic customers and entered new geographies
- Healthy influx of inquiries from key developed markets for recently launched and new pipeline of products



Crop Protection - Performance Highlights

- Revenue stood at INR 194 Cr witnessing -17% change on YoY basis due to
 - Supply chain disruptions in the global market on account of current geo-political situation
- EBIT stood at INR 12 Cr due to
 - Input cost inflationary pressures on raw materials, energy and solvents
 - Lag in pass through of costs to end-customers
- Demand for agrochemicals continues to remain strong for both CDMO and Own Products segment
- Enhanced inquiries from global innovator companies for CDMO segment owing to China-plus-one strategy
- Strong traction from a diverse set of global customers for the pipeline of new products
- Ongoing capex at Panoli, Gujarat to be commissioned during second half of the financial year 2022-23




Quarterly Financial Highlights



Consolidated Revenue

Consolidated EBITDA


Consolidated PAT




Rs. Crore

Quarterly Segmental Highlights


Pharmaceuticals Revenue




Crop Protection Revenue



Pharmaceuticals EBIT



Crop Protection EBIT



Consolidated Profit & Loss - Q4 FY22

Particulars (Rs. Crore)	Q4 FY22	Q4 FY21	Y-o-Y	Q3 FY22	Q-o-Q
Net Sales	502	532	-6%	514	-2%
Expenditure	441	423		420	
EBITDA	61	109	-44%	93	-34%
Margin	12.2%	20.5%		18.3%	
Other Income	0	3		-1	
Depreciation	24	22		24	
Finance Costs	8	8		7	
PBT	29	81	-64%	62	-53%
Tax	8	30		16	
Net Profit	21	51	-59%	46	-54%
Margin	4.1%	9.8%		8.8%	



Annual Financial Highlights

Financial Highlights - Annual



Revenue – FY22
Rs. 1,943 Crore

↑ FY18-22 CAGR 11% ↑ YoY 13%



EBITDA – FY22
Rs. 341 Crore

↑ FY18-22 CAGR 9% ↑ YoY 5%



EBITDA Margin – FY22
17.5%

↓ YoY -124bps



PAT – FY22
Rs. 161 Crore


↑ FY18-22 CAGR 20% ↑ YoY 21%




EPS – FY22
Rs 13.02

↑ FY18-22 CAGR 20% ↑ YoY 21%


Annual Performance Highlights



Pharmaceuticals Division



Crop Protection Division






Yearly Financial Highlights



Consolidated Revenue

Consolidated EBITDA


Consolidated PAT




Rs. Crore

Sales Break-Up

Pharmaceuticals Revenue Break-Up




Crop Protection Revenue Break-Up




Yearly Segmental Highlights


Pharmaceuticals Revenue




Crop Protection Revenue



Pharmaceuticals EBIT



Crop Protection EBIT



Consolidated Profit & Loss - Full Year

Particulars (Rs. Crore)	FY22	FY21	Y-o-Y
Net Sales	1,943	1,720	13%
Expenditure	1,602	1,397	
EBITDA	341	323	3%
Margin	17.5%	18.8%	
Other Income	5	5	
Depreciation	96	85	
Finance Costs	31	36	
Exceptional Item	-	-	
PBT	219	206	6%
Tax	58	73	
Net Profit	161	133	21%
Margin	8.3%	7.7%	

Consolidated Balance Sheet

Assets (Rs. Crore)	Mar-22	Mar-21
Total Non Current Assets	1,249	1,035
Property, Plant and Equipment	815	646
Capital work in Progress	285	245
Right to Use Assets	64	65
Other Intangible Assets	1	1
Intangible Assets Under Development	10	9
Financial Assets		
Investments	1	1
Loans	0	0
Other	15	20
Income Tax Assets (Net)	2	2
Other Non Current Assets	57	45
Total Current Assets	964	1,035
Inventories	329	267
Financial Assets		
Current Investment	10	0
Trade Receivables	438	486
Cash & Cash Equivalents	11	8
Bank Balances	38	29
Loans	0	0
Other	17	0
Other Current Assets	120	89
TOTAL ASSETS	2,213	1,913


Equities & Liabilities (Rs. Crore)	Mar-22	Mar-21
Shareholders Fund	1,068	933
Share Capital	25	25
Other Equity	1,043	909
Total Non Current Liabilities	376	324
Financial Liabilities		
Borrowings	287	263
Lease Liability	0	1
Provisions	24	22
Deferred Tax Liabilities (net)	36	38
Other non current liabilities	29	0
Total Current Liabilities	769	656
Financial Liabilities		
Borrowings	388	346
Lease Liability	0	0
Trade Payables	249	230
Other Financial Liabilities	68	41
Other Current Liabilities	48	12
Provisions	3	4
Current Tax Liabilities (Net)	12	23
TOTAL EQUITY & LIABILITIES	2,213	1,913

Consolidated Cash Flow Statement


Particulars (Rs. Crore)	Full Year ended 31-Mar-22 Full Year ended 31-Mar-21	
Profit before tax	219	206
<i>Adjustments</i>	128	127
Operating Profit Before Working Capital Changes	345	333
<i>Change in operating assets and liabilities</i>	19	(58)
Cash generated from operations	364	276
<i>Income taxes paid</i>	70	47
Net cash inflow from operating activities (A)	294	229
Net cash inflow/(outflow) from investing activities (B)	(284)	(156)
Net cash outflow from financing activities (C)	(6)	(97)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	3	(24)
Cash and cash equivalents at the beginning of the year	8	32
Cash and cash equivalents at the end of the year	11	8

Ratio Analysis


ROE




ROCE



Net Debt / Equity




Net Debt / EBITDA



Annual Dividend Payout

Dividend Payout including DDT



The above dividend is based on Face Value of Rs. 2 per share



Company :

Hikal Limited

CIN: L24200MH1988PTC048028

Mr. Kuldeep Jain

Kuldeep_jain@hikal.com

www.hikal.com

SGA Strategic Growth Advisors

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Aakash Mehta

+91-9920602034 / +91-9819178243

jigar.kavaiya@sgapl.net / aakash.mehta@sgapl.net

www.sgapl.net

HIKAL
